Resveratrol may have therapeutic value in the treatment of metabolic syndrome. - GreenMedInfo Summary
Resveratrol: a relevant pharmacological approach for the treatment of metabolic syndrome?
Curr Opin Clin Nutr Metab Care. 2010 Nov;13(6):729-36. PMID: 20823772
EA 4466 Stress cellulaire: physiopathologie, stratégies nutritionnelles et innovations thérapeutiques, Faculté de Pharmacie Paris Descartes, hôpital Charles Foix, APHP, Paris, France.
PURPOSE OF REVIEW: The metabolic syndrome is associated with increased risk for development of both cardiovascular disease and type 2 diabetes in humans. Because experimental data and clinical experience have shown that metabolic syndrome and caloric restriction have, at least partly, opposite pathophysiological pathways, the activation of sirtuins may constitute a pharmacological approach to treat metabolic syndrome. Resveratrol is a polyphenol produced by plants that has multiple beneficial activities similar to those associated with caloric restriction.
RECENT FINDINGS: Through its regulatory action of both AMP kinase and the sirtuin sirtuin-1, resveratrol is a natural sirtuin activator that certainly will be the head of a new pharmacological family of drugs targeted on sirtuin-1 activity exacerbation in order to treat/protect from obesity and diabetes, and thus metabolic syndrome.
SUMMARY: This review discusses the therapeutic use of resveratrol and sirtuin activators in the context of insulin resistance and obesity, the two main features of metabolic syndrome.